RENO, Nev., August 26, 2003 (PRIMEZONE) -- Altair Nanotechnologies Inc. (Nasdaq:ALTI) announced that its President, Dr. Rudi Moerck, will be presenting to members of the financial community at The Wall Street analyst Forum's pharmaceutical conference in New York on September 16, 2003. Dr. Moerck will provide an overview of Altair Nanotechnologies and an in-depth discussion of the company's patent-pending pharmaceutical candidate, RenaZorb(tm), and its new nano-based drug delivery system.
RenaZorb is a new non-calcium pharmaceutical for removal of phosphate from patients with end-stage renal disease that are undergoing kidney dialysis. RenaZorb removed phosphate in laboratory tests using simulated stomach fluid and has also demonstrated phosphate binding in three animal models. The phosphate capacity and rapid rate of reaction is excellent for this class of drug. New testing of RenaZorb in animals with end stage renal disease will be reported.
A study of Altair's nanomaterials and patented porous nano-structures for drug delivery systems and pharmaceutical sustained release applications is underway. The study is for both existing pharmaceuticals and for new active pharmaceutical ingredients. Altair's delivery system has the potential of extending the patent life of existing drugs which could preserve important revenue streams for pharmaceutical companies.
The conference is being held at the Roosevelt Hotel located on Madison Avenue at 45th Street, second floor. Dr. Moerck will be presenting at 9:40 AM on Tuesday, September 16. For information or to RSVP, please call 802.253.7596.
Altair Nanotechnologies Inc.
Nanotechnology is rapidly emerging as a unique industry sector. Altair Nanotechnologies is positioning itself through product innovation within this emerging industry to become a leading supplier of nanomaterials and technology worldwide. Altair owns a proprietary technology for making nanocrystalline materials of unique quality both economically and in large quantities. The company is currently developing special nanomaterials with potential applications in pharmaceuticals, fuel cells, solar cells, advanced energy storage devices, thermal spray coatings, catalysts, paints and environmental remediation. For additional information on Altair's nanoparticle materials, visit www.altairnano.com.
Forward-Looking Statements
This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause the company's actual and future results to be materially different than suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the successful testing, FDA approval and commercialization of RenaZorb, the company may be unable to attract or form relationships with pharmaceutical companies, or have the funds necessary to development additional products or create product opportunities within the pharmaceutical industry, in addition to other risks identified in the company's most recent Annual Report on Form 10-K, as filed with the SEC. Such forward-looking statements speak only as of the date of this release. The company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in company expectations or results or any change in events.
The Altair Nanotechnologies Inc. company logo can be found at: http://media.primezone.com/prs/single/?pkgid=511